Blog
Latest articles, insights, and updates from the blog.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
Subcutaneous Ketamine: Clinical Use, Onset, and Bioavailability
How subcutaneous ketamine works, its bioavailability vs IV, clinical settings where it's used, and questions to discuss with a licensed clinician.
Shared Serotonin Signal Found in Two Fast Antidepressants
New research finds a shared serotonin mechanism across two rapid-acting depression treatments, reshaping how clinicians and patients understand how these drugs work.
BPL-003 Reaches Phase III in Treatment-Resistant Depression
AtaiBeckley advances BPL-003 into Phase III for treatment-resistant depression. What this milestone means for patients and the TRD treatment landscape.
New Study: Ketamine Relieves Treatment-Resistant Depression
A new study reports ketamine relieves treatment-resistant depression and suicidal ideation. What the research means for patients exploring their options.
Ketamine Onset Time by Route: What the Research Shows
How quickly does ketamine work? Onset ranges from 30 seconds (IV) to 30 minutes (oral). Compare bioavailability, duration, and supervision needs by route.
Ketamine for Depression: Why Your GP Stays Silent
Ketamine is producing real results for treatment-resistant depression, yet most GPs don't raise it. Here's what patients need to know about access and options.
Ketamine vs Antidepressants: A Complete Comparison
How ketamine compares to traditional antidepressants: speed, mechanism, who they help, side effects, and how they may work together. Patient education.
Compounded Ketamine vs Spravato: Key Differences Explained
Compare compounded ketamine and Spravato (esketamine): FDA approval, bioavailability, supervision requirements, and clinical access differences.
Nevada Mental Health Expands Ketamine Treatment Access
Nevada Mental Health grows ketamine program through interventional psychiatry, signaling expanded access to innovative depression treatments.
New Study Shows IV Ketamine Beats Nasal Esketamine
Recent research reveals IV ketamine achieves higher remission rates than nasal esketamine for depression treatment. What this means for patients.
Psychiatrist Outlines Key Ketamine Patient Considerations
Dr. Benjamin Brody highlights critical patient considerations for ketamine treatment at major psychiatric conference. Key insights for treatment seekers.
Esketamine for Treatment-Resistant Depression: How It Works
How esketamine (Spravato) is used for treatment-resistant depression: eligibility, the REMS program, dosing schedule, side effects, and contraindications.
Is Ketamine a Controlled Substance? Schedule III Status Explained
Ketamine is a Schedule III controlled substance under US federal law. Learn what that classification means for prescribing, dispensing, and patient access.